Circulating Cell-Derived Microparticles in Severe Preeclampsia and in Fetal Growth Restriction

American Journal of Reproductive Immunology

Volumn 67, Issue 2, 2012, Pages 140-151

  Alijotas Reig, Jaume ^a,b   Palacio Garcia, Carles ^a   Farran Codina, Immaculada ^a   Ruiz Romance, Mar ^a   Llurba, Elisa ^a   Vilardell Tarres, Miquel ^a,b  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Antiphospholipid antibodies; Cell derived microparticles; Fetal growth restriction; Severe preeclampsia HELLP syndrome

Indexed keywords

CD31 ANTIGEN; CD45 ANTIGEN; FIBRINOGEN RECEPTOR; LIPOCORTIN 5; PHOSPHOLIPID ANTIBODY; VASCULAR ENDOTHELIAL CADHERIN;

ADULT; ARTICLE; CASE CONTROL STUDY; CELL COUNT; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; GESTATIONAL AGE; HELLP SYNDROME; HUMAN; HUMAN CELL; INTRAUTERINE GROWTH RETARDATION; LEUKOCYTE; MAJOR CLINICAL STUDY; MEMBRANE MICROPARTICLE; PREECLAMPSIA; PREGNANT WOMAN; PRIORITY JOURNAL; SMOKING HABIT; THROMBOCYTE COUNT;

ADULT; ANNEXIN A5; ANTIBODIES, ANTIPHOSPHOLIPID; ANTIGENS, CD; ANTIGENS, CD31; ANTIGENS, CD45; BLOOD PLATELETS; CADHERINS; CASE-CONTROL STUDIES; CELL COUNT; CELL-DERIVED MICROPARTICLES; CYTOKINES; ENDOTHELIAL CELLS; FEMALE; FETAL GROWTH RETARDATION; HUMANS; PLATELET MEMBRANE GLYCOPROTEIN IIB; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY COMPLICATIONS;

EID: 84855357689     PISSN: 10467408     EISSN: 16000897     Source Type: Journal    
DOI: 10.1111/j.1600-0897.2011.01072.x     Document Type: Article

References (46)

1. Solomon CG, Seely EW: Preeclampsia-searching for the cause. N Engl J Med 2004; 350:641-643.
2. Llurba E, Casals E, Dominguez C, Delgado J, Mercadé I, Crispi F, Cabero L, Gratacos E: Atherogenic lipoprotein subfraction profile in preeclamptic women with and without high tryglicerides: different pathophysiologic subsets in preeclampsia. Metabolism 2005; 54:504-509.
3. ACOG Parctice Bulletin No 33: Diagnosis and management of preeclampsia and eclampsia. Obstet Gynecol 2002; 99:159-166.
4. Martin JN, Rose CH, Briery CM: Understanding and managing HELLP syndrome: the integral role of aggressive glucocorticoids for mother and child. Am J Obstet Gynecol 2006; 195:914-934.
5. Mello G, Parretti E, Marozio L, Pizzi C, Lojacono A, Frusca T, Facchinetti F, Benedetto C: Thrombophilia is significantly associated with severe preeclampsia. Hypertension 2005; 46:1270-1274.
6. Wilczynski JR: Immunological analogy between allograft rejection, recurrent abortion and pre-eclampsia - the same basic mechanism? Hum Immunol 2006; 67:492-511.
7. Levine RJ, Lam Ch, Qian C, Yu KF, Maynard SE, Sachs BP, Sibai BM, Epstein FH, Romero R, Thadhani R, Karumanchi A: Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 2006; 355:992-1005.
8. Alijotas-Reig J, Ferrer-Raventos JC: Recurrent miscarriage and inherited thrombophilia: diagnostic work-out and therapeutic management. Med Clin (Barc) 2005; 125:626-631.
9. Khong TY, De Wolf F, Robertson WB, Brosens I: Inadequate maternal vascular response to placentation in pregnancies complicated by preeclampsia and by small gestational age for infants. Br J Obstet Gynecol 1986; 10:1049-1059.
10. Scifres CM, Nelson DM: Intrauterine growth restriction, human placental development and trophoblast cell death. J Physiol 2009; 587(Pt 14):3453-3458.
11. Lingheimer MD, Umans JG: Explaining and predicting preeclampsia. N Engl J Med 2006; 355:1056-1057.
12. Taylor RN: Review: immunobiology of preeclampsia. Am J Reprod Immunol 1997; 37:79-86.
13. Labarrere CA, Faulk WP: Intercellular adhesión molecule-I (ICAM-1) and HLA-DR antigens are expressed on endovascular cytotrophoblast in abnormal pregnancies. Am J Reprod Immunol 1995; 33:47-53.
14. Taylor RN, De Groot C, Cho YK, Lim HK: Circulating factors as markers and mediators of endothelial cell dysfunction in preeclampsia. Semin Repord Endocrinol 1998; 16:17-31.
15. Dignat-George F, Camoin-Jau L, Sabatier F, Arnaux D, Anfosso F, Bardin N, Veit V, Combes V, Gentile S, Moal V, Sanmarco M, Sampol J: Endothelial microparticles: a potential contribution to the thrombotic complications of the antiphospholipid syndrome. Throm Haemost 2004; 91:667-673.
16. Branch DW, Rodgers GM: Induction of endothelial cell tissue factor activity by sera from patients with antiphospholipid syndrome: a possible mechanism of thrombosis. Am J Obstet Gynecol 1993; 168:206-210.
17. Meroni PL: Endothelial cell perturbation by anti-phospholipid antibodies in systemic lupus erythematosus. Lupus 2007; 16(Suppl.):17-19.
18. Koike T: Antiphospholipid antibodies and cell activation. Lupus 2007; 16(Suppl.):17.
19. Meroni PL, Borghi MO, Raschi E, Ventura D, Sarzi Puttini PC, Atzeni F, Lonati L, Parati G, Tincani A, Mari D, Tedesco F: Inflammatory response and the endothelium. Thromb Res 2004; 114:329-334.
20. Distler JH, Pisetsky DS, Huber L, Kalden JR, Gay S, Distler O: Microparticles as regulators of inflammation: novel players of cellular crosstalk in the theumatic diseases. Arthritis Rheum 2005; 52:3337-3348.
21. Alijotas-Reig J, Vilardell-Tarrés M: Is obstetric antiphospholipid syndrome a primary nonthrombotic, proinflammatory, complement-mediated disorder related to antiphospholipid antibodies?. Obstet Gynecol Surv 2010; 65:39-45.
22. Girardi G, Yarilin D, Thurman JM, Holers VM, Salmon JE: Complement activation induces dysregulation of angiogenic factors and causes fetal rejection and growth restriction. J Exp Med 2006; 203:2165-2175.
23. Ruiz-Romance M. Clinical Usefulness of Cell-Derived Circulant Microparticles in Recurrent Miscarriage, Preeclampsia and in Fetal Growth Restriction. Doctoral Thesis, Barcelona (Spain), Universitat Autonoma, 2010.
24. Germain SJ, Sacks GP, Soorana SR, Sargent IL: Systemic inflammatory priming in normal pregnancy and preeclampsia: the role of circulating syncytiotrophoblast microparticles. J Immunol 2007; 178:5949-5956.
25. Carp H, Dardik R, Lubetsky A, Salomon O, Eskaraer R, Rosenthal E, Inbal A: Prevalence of circulating procoagulant microparticles in women with recurrent miscarriage: a case-controlled study. Hum Reprod 2004; 19:191-195.
26. Omatsu K, Kobayashi T, Murakami Y, Suzuki M, Ohashi R, Sugimura M, Nakayama N: Phophatidylserine/phosphatidylcholine microvesicles can induce pre-eclampsia-like changes in pregnant mice. Semin Thromb Haemost 2005; 31:314-320.
27. Bretelle F, Sabatier F, Desprez D, Camoin L, Grunebaum L, Combes V, D'Ercole C, Dignat-George F: Circulating microparticles: a marker of procoagulant state in normal pregnancy and pregnancy complicated by preeclampsia or intrauterine growth restriction. Thromb Haemost 2003; 89:486-492.
28. Gonzalez-Quintero VH, Smarkusky LP, Jimenez JJ, Mauro LM, Wenche JI, Hortsman L, O'Sullivan MJ, Ahn YS: Elevated plasma endothelia microparticles: preeclampsia. Versus gestational hypertension. Am J Obstet Gynecol 2004; 191:1418-1424.
29. VanWijk MJ, Nieuwland R, Boer K, Van der Post JA, vanBavel E, Sturk A: Microparticle subpopulations are increased in preeclampsia: possible involvement in vascular dysfunction? Am J Obstet Gynecol 2002; 187:450-456.
30. Report of the national high blood pressure education program working group on high blood presuure in pregnancy. Am J Obstet Gynecol 2000; 188:S1-S22.
31. Sibai BM: Diagnosis, controversies and management of the syndrome of haemolysis, elevated liver enzymes, and low platelet count. Am J Obstet Gynecol 2004; 103:981-991.
32. Soothill PW, Bobrow CS, Holmes R: Small for gestational age is not a diagnosis. Ultrasound Obstet Gynecol 1999; 13:225-228.
33. Brandt JT, Tripplet DA, Alving B, Scharrer I: Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the subcommittee on lupus anticoagulants/antiphospholipid antibody of the scientific and standardisation of the ISTH. Thromb Haemost 1995; 126:555-564.
34. Chironi GN, Boulanger CM, Simon A, Dignat-george F, Freyssinet JM, Tedgui A: Endothelial microparticles in diseases. Cell Tissue Res 2009; 335:143-151.
35. Lok CA, Van Der Post JA, Sargent IL, Hau CM, Sturk A, Boe K, Nieuwland R: Changes in microparticle number and cellular origin during pregnancy and preeclampsia. Hypertens Pregnancy 2008; 27:344-360.
36. Joop K, Nieuwland R, Berrckmans RJ, Berkhout J, Romijin FP, Hack CE, Sturk A: Microparticles from patients with multiple organ dysfunction syndrome and sepsis support coagulation through multiple mechanism. Thromb Haemost 2001; 85:810-820.
37. Mesri M, Altieri DC: Endothelial cell activation by leukocyte microparticles. J Immunol 1998; 16:4382-4387.
38. Biró E, Lok CAR, Hack CE, Van der Post JAM, Schaap MCL, Sturk A, Nieuwland R: Cell-derived microparticles and complement activation in pre-eclampsia versus normal pregnancy. Placenta 2007; 28:928-935.
39. Sellam J, Proulle V, Jüngel A, Ittah M, Miceli-Richard C, Gottenberg JE, Toti F, Benessiano J, Gay S, Freyssenet JM, Mariette X: Increased levels of circulating microparticles in primary Sjögren's syndrome, systemic lupus erythematosus and rheumatoid arthritis with disease activity. Arthritis Res Ther 2009; 11:R156.
40. Lok CA, Böing AN, Sargent IL, Sooranna SR, Van der Post JA, Newland R, Sturk A: Circulating platelet-derived and placental-derived microparticles expose Flt-1 in preeclampsia. Reprod Sci 2008; 15:1002-1010.
41. Alijotas-Reig J, Farrán-Codina I, Palacio-Garcia C, Ruiz M, Casellas-Caro M, Vilardell-Tarrés M: Microparticles, obstetric morbidity and antiphospholipid antibodies. Seventh Meeting of the European Forum on Antiphospholipid Antibodies. October 2-3, 2009, Marseille.
42. Combes V, Simon AC, Grau GE, Arnoux D, Camoin L, Sabatier F, Mutin M, Sanmarco M, Sanpol J, Dignat-George F: In vitro generation of endothelial microparticles and possible prothrombotic activity in patients with lupus anticoagulant. J Clin Invest 1999; 104:93-102.
43. Pereira J, Alfaro G, Goycoolea M, Quiroga T, Ocqueteau M, Massardo L, Perez C, Saez C, Panes O, Matus V, Mezzano D: Circulating platelet-derived microparticles in systemic lupus erythematosus. Association with increased thrombin generation and procoagulant state. Thromb Haemost 2006; 95:94-99.
44. Goswami D, Tannetta DS, Magee LA, Fuchisawa A, Rednan CW, Sargent IL, von Dadelszen P: Excess syncytiotrophosblast microparticles shedding is a feature of early-onset pre-eclampsia, but not normotensive intrauterine growth restriction. Placenta 2006; 27:56-61.
45. Jy W, Horstman LL, Jinmenez JJ, Ahn YS: Measuring circulating cell-derived microparticles. J Thromb Hemost 2004; 2:1842-1843.
46. Shet AS: Characterizing blood microparticles: technical aspects and challenges. Vasc Health Risk Manag 2008; 4:769-774.